
OrthoGrid Systems is owned by Zimmer Biomet, a publicly traded American medical device company headquartered in Warsaw, Indiana. OrthoGrid Systems was acquired by Zimmer Biomet in 2024 and specializes in AI-powered surgical guidance technology for orthopedic procedures. The company is listed on NASDAQ under ticker ZBH.
Parent Company
Acquired
2024
Status
Publicly Traded
Headquarters
| Brand | Parent Company | Ownership Type |
|---|---|---|
| OrthoGrid Systems | Zimmer Biomet Holdings, Inc. | Wholly owned |
OrthoGrid Systems was founded in 2016 as a medical technology company focused on developing AI-powered surgical guidance systems for orthopedic procedures. The company developed innovative technology to assist surgeons in achieving optimal implant positioning and alignment during orthopedic surgeries, particularly hip replacement procedures.
Throughout the late 2010s and early 2020s, OrthoGrid Systems expanded its technology platform and clinical evidence base, establishing itself as a leader in AI-assisted surgical guidance. The company became known for its advanced computer vision and artificial intelligence capabilities that enhanced surgical precision and patient outcomes.
In 2024, OrthoGrid Systems was acquired by Zimmer Biomet to expand Zimmer Biomet's market share in hip replacement procedures and integrate AI-powered surgical guidance into Zimmer Biomet's comprehensive orthopedic portfolio. Under Zimmer Biomet's ownership, OrthoGrid Systems continues to innovate in AI surgical guidance while benefiting from Zimmer Biomet's global distribution network and research resources.
Is Zimmer Biomet publicly traded?
Yes. Zimmer Biomet Holdings, Inc. trades on the New York Stock Exchange under the ticker symbol ZBH. The company is also listed on the SIX Swiss Exchange. Zimmer Biomet is a component of the S&P 500 index. The company was first spun off from Bristol Myers Squibb in August 2001 and has been independently traded since then.
When was Zimmer Biomet founded?
Zimmer Biomet traces its origins to 1927, when Justin O. Zimmer founded Zimmer Manufacturing Company in Warsaw, Indiana, to produce aluminum splints. The modern Zimmer Biomet Holdings, Inc. was incorporated in Delaware in 2001 and was formed through the acquisition of Biomet, Inc. in June 2015, at which point the company changed its name from Zimmer Holdings, Inc. to Zimmer Biomet Holdings, Inc.
Where is Zimmer Biomet headquartered?
Zimmer Biomet is headquartered at 345 East Main Street, Warsaw, Indiana 46580, USA. Warsaw, Indiana, is a major hub for the orthopedic device industry, with Zimmer Biomet as one of its anchor companies. The company operates manufacturing and distribution facilities across the United States, Europe, Asia, and Latin America.
What products does Zimmer Biomet make?
Zimmer Biomet manufactures orthopedic reconstructive products (knee, hip, shoulder, elbow replacements), sports medicine and biologics products, extremities and trauma products, craniomaxillofacial and thoracic products, bone cement, surgical products, and integrated digital and robotic technologies. Key product platforms include ROSA Robotic Solutions, Persona OsseoTi Keel Tibia, Oxford Cementless Partial Knee, Z1 Femoral Hip System, and iTaperloc Complete and iG7 Hip System with iodine-treated implants.
What are Zimmer Biomet's major acquisitions?
Zimmer Biomet's most significant acquisition was Biomet, Inc. in June 2015 for approximately $14.0 billion, which created the current company. Other major acquisitions include Centerpulse AG (2003, $3.2 billion), LDR Holding Corporation (2016, $1 billion), Paragon 28 (April 2025, $1.2 billion), OrthoGrid Systems (2024), Monogram Technologies (2025), and the iovera pain therapy business from Pacira BioSciences (2026, $140 million).
What is ZimVie?
ZimVie Inc. (NASDAQ: ZVIE) is an independent public company that was spun off from Zimmer Biomet in March 2022. ZimVie operates Zimmer Biomet's former spine and dental business. The spin-off allowed Zimmer Biomet to focus on its core orthopedic reconstructive and sports medicine businesses. ZimVie is no longer part of Zimmer Biomet.
Who is the CEO of Zimmer Biomet?
Ivan Tornos serves as Chairman, President, and CEO of Zimmer Biomet. Tornos was appointed CEO in 2023, succeeding Bryan Hanson. Under Tornos's leadership, the company has focused on its "Magnificent Seven" innovation platforms, completed three transformative acquisitions, and initiated a transition to a direct sales model in the U.S.
What is Zimmer Biomet's revenue?
Zimmer Biomet reported FY2025 (ended December 31, 2025) net sales of $8.23 billion, up 7.2% from $7.68 billion in FY2024. Net earnings were $705.1 million, and adjusted net earnings were $1.63 billion. Diluted EPS was $3.55, and adjusted diluted EPS was $8.20. For Q1 2026, net sales were $2.09 billion, up 9.3%, with net earnings of $238.1 million and diluted EPS of $1.22.
OrthoGrid Systems operates under Zimmer Biomet's sustainability framework, focusing on responsible AI development, environmental compliance in medical device manufacturing, and ethical healthcare innovation.
Responsible AI Development: OrthoGrid Systems maintains ethical standards for AI development and deployment in surgical settings. The company's AI systems undergo validation to ensure accuracy, reliability, and patient safety. OrthoGrid implements transparent AI algorithms with explainable decision-making processes, enabling surgeons to understand and trust AI-guided surgical recommendations.
Environmental Compliance in Manufacturing: As part of Zimmer Biomet's operations, OrthoGrid Systems' technology components are manufactured following environmental standards. The company maintains compliance with environmental regulations across its supply chain.
Medical Device Regulatory Compliance: OrthoGrid Systems maintains regulatory compliance across all markets where its AI surgical guidance technology is deployed. The company's systems meet FDA requirements for medical device software, CE marking for European markets, and other international medical device regulations.
Data Privacy and Security: OrthoGrid Systems implements data privacy and security measures for patient data used in AI algorithms. The company follows HIPAA compliance standards and other healthcare data protection regulations. Patient data used for AI training and surgical guidance is anonymized and processed according to strict privacy protocols.
Sustainable Healthcare Innovation: OrthoGrid Systems' AI technology contributes to sustainability in healthcare by improving surgical precision, reducing procedure times, and minimizing revision surgeries. Enhanced surgical accuracy through AI guidance reduces medical waste associated with failed procedures.
OrthoGrid Systems has received recognition for innovation in AI-powered surgical guidance technology.
Medical Technology Innovation: OrthoGrid Systems has received recognition from medical technology organizations for its AI-powered surgical guidance systems. The company's technology has been acknowledged for advancing surgical precision through artificial intelligence, particularly in hip replacement procedures.
AI and Healthcare Recognition: The company has received awards from AI and healthcare technology organizations for responsible AI development in medical applications. OrthoGrid Systems' approach to explainable AI in surgical settings has been recognized for setting standards for transparency in AI-assisted healthcare procedures.
Clinical Excellence Recognition: OrthoGrid Systems' technology has been recognized by orthopedic surgical societies and clinical organizations for its contribution to improving surgical outcomes. The company's AI guidance systems have been acknowledged for helping surgeons achieve better implant positioning and alignment.
Startup and Innovation Awards: Prior to its acquisition by Zimmer Biomet, OrthoGrid Systems received recognition from startup and innovation organizations for its rapid development and commercialization of AI surgical guidance technology.
As a relatively young medical technology company acquired in 2024, OrthoGrid Systems has not faced major product recalls or significant controversies. However, the company operates in a highly regulated medical device environment where AI applications face scrutiny and regulatory challenges.
Regulatory Compliance Challenges: OrthoGrid Systems faces ongoing regulatory scrutiny as an AI-powered medical device company. The company must navigate complex FDA requirements for medical device software, including pre-market approval, post-market surveillance, and algorithm validation. These regulatory requirements create compliance burdens and potential delays in technology deployment that are typical for innovative medical AI applications.
AI Ethics and Bias Concerns: Like all AI medical device companies, OrthoGrid Systems faces scrutiny regarding potential algorithmic bias in its surgical guidance systems. The company must address concerns about whether AI algorithms perform consistently across different patient demographics, surgical techniques, and healthcare settings. OrthoGrid has implemented extensive testing and validation processes to address these concerns.
Data Privacy and Security Risks: OrthoGrid Systems' use of patient data for AI algorithm training and improvement creates potential privacy and security risks. The company must maintain strict compliance with healthcare data protection regulations including HIPAA in the United States and GDPR in Europe. Any data breaches or privacy violations could have significant consequences for the company and its healthcare partners.
Technology Adoption Challenges: OrthoGrid Systems faces challenges in convincing surgeons to adopt AI-powered surgical guidance technology. Some surgeons may be skeptical of AI assistance in surgical decision-making, requiring extensive clinical evidence and validation studies. The company must overcome traditional resistance to new technology in surgical practice.
Competition and Market Pressure: The AI surgical guidance market is becoming increasingly competitive, with established medical device companies and startups developing similar technologies. OrthoGrid Systems faces pressure to continuously innovate and differentiate its AI technology to maintain its market position following the Zimmer Biomet acquisition.
Integration Challenges: Following its 2024 acquisition by Zimmer Biomet, OrthoGrid Systems faces integration challenges typical of acquired companies. The company must adapt to Zimmer Biomet's corporate culture, processes, and strategic priorities while maintaining its innovative AI development capabilities and entrepreneurial spirit.
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Ge Healthcare | USA | 1994 | Premium | Global | All-ages |
Market Positioning: OrthoGrid Systems competes with 1 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Looking for brands with different ownership structures? These similar brands are not owned by Zimmer Biomet Holdings, Inc., giving you alternative choices that support different corporate structures.
Healthcare PharmaceuticalsOwned by GE HealthCare Technologies Inc.
Independent publicly traded healthcare technology company spun off from General Electric in January 2023, providing medical imaging, diagnostics, and healthcare IT solutions globally.
GE HealthCare operates independently without a large parent corporation.
Healthcare PharmaceuticalsOwned by Koninklijke Philips N.V.
Health technology brand owned by Koninklijke Philips N.V., a publicly traded Dutch company listed on Euronext Amsterdam (PHIA). Covers medical imaging, patient monitoring, and personal health products.
Philips operates independently without a large parent corporation.
Healthcare PharmaceuticalsOwned by Pfizer Inc.
American multinational pharmaceutical corporation developing and manufacturing medicines, vaccines, and consumer healthcare products, one of the world's largest pharmaceutical companies.
Pfizer operates independently without a large parent corporation.
Healthcare PharmaceuticalsOwned by IBSA Institut Biochimique S.A.
IBSA Institut Biochimique SA's branded levothyroxine softgel capsule (Tirosint) and liquid solution (Tirosint-SOL), FDA approved for hypothyroidism, formulated without dyes, gluten, lactose, alcohol, or sugar, providing an excipient-free alternative to conventional levothyroxine tablets for patients with sensitivities or absorption issues.
Tirosint is privately owned, unlike OrthoGrid Systems which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Alcon Inc.
Independent publicly traded global eye care company headquartered in Geneva, Switzerland, specializing in surgical equipment, contact lenses, and ophthalmic products. Spun off from Novartis in April 2019.
Alcon operates independently without a large parent corporation.
Healthcare PharmaceuticalsOwned by Herbalife Ltd.
Global nutrition and weight-management brand owned by Herbalife Ltd. and sold through independent distributors in more than 90 markets.
Herbalife operates independently without a large parent corporation.
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.

Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.

Prescription isotretinoin brand developed by Roche and approved by the FDA in 1982 for severe nodular acne. Roche discontinued the brand name in the United States in 2009; the drug continues as Roaccutane in international markets.

Activase (alteplase) is a prescription thrombolytic medication manufactured by Genentech, a wholly-owned subsidiary of Roche. Used to treat acute ischemic stroke, heart attack, and pulmonary embolism.